Loss of HNF1α Function Contributes to Hepatocyte Proliferation and Abnormal Cholesterol Metabolism via Downregulating miR-122: A Novel Mechanism of MODY3

References

• Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345(13):971–980. doi:10.1056/NEJMra002168
   PubMed Web of Science ®Google Scholar
• Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384(6608):455–458. doi:10.1038/384455a0
   PubMed Web of Science ®Google Scholar
• Ellard S, Bellanne-Chantelot C, Hattersley AT. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51(4):546–553. doi:10.1007/s00125-008-0942-y
   PubMed Web of Science ®Google Scholar
• Blumenfeld M, Maury M, Chouard T, Yaniv M, Condamine H. Hepatic nuclear factor 1 (HNF1) shows a wider distribution than products of its known target genes in developing mouse. Development. 1991;113(2):589–599.
   PubMedGoogle Scholar
• Pontoglio M, Sreenan S, Roe M, et al. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest. 1998;101(10):2215–2222. doi:10.1172/JCI2548
   PubMed Web of Science ®Google Scholar
• Yamagata K, Nammo T, Moriwaki M, et al. Overexpression of dominant-negative mutant hepatocyte nuclear factor-1 alpha in pancreatic beta-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced beta-cell proliferation, and diabetes. Diabetes. 2002;51(1):114–123. doi:10.2337/diabetes.51.1.114
   PubMedGoogle Scholar
• Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev. 2002;54(1):129–158. doi:10.1124/pr.54.1.129
   PubMedGoogle Scholar
• Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology. 2003;125(5):1470–1475. doi:10.1016/j.gastro.2003.07.012
   PubMedGoogle Scholar
• Reznik Y, Dao T, Coutant R, et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab. 2004;89(3):1476–1480. doi:10.1210/jc.2003-031552
   PubMedGoogle Scholar
• Willson JS, Godwin TD, Wiggins GA, Guilford PJ, McCall JL. Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation. J Hepatol. 2013;59(4):904–907. doi:10.1016/j.jhep.2013.05.024
   PubMedGoogle Scholar
• McDonald TJ, McEneny J, Pearson ER, et al. Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta. 2012;413(9–10):927–932. doi:10.1016/j.cca.2012.02.005
   PubMedGoogle Scholar
• Bellanne-Chantelot C, Levy DJ, Carette C, et al. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J Clin Endocrinol Metab. 2011;96(8):E1346–E1351. doi:10.1210/jc.2011-0268
   PubMedGoogle Scholar
• Huang X, Gong S, Ma Y, et al. Lower circulating miR-122 level in patients with HNF1A variant-induced diabetes compared with type 2 diabetes. J Diabetes Res. 2018;2018:7842064. doi:10.1155/2018/7842064
   PubMedGoogle Scholar
• Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735–739. doi:10.1016/S0960-9822(02)00809-6
   PubMed Web of Science ®Google Scholar
• Xu H, He JH, Xiao ZD, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology. 2010;52(4):1431–1442. doi:10.1002/hep.23818
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–689. doi:10.1038/nature04303
   PubMed Web of Science ®Google Scholar
• Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (New York, NY). 2005;309(5740):1577–1581. doi:10.1126/science.1113329
   Google Scholar
• Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009;284(46):32015–32027. doi:10.1074/jbc.M109.016774
   PubMed Web of Science ®Google Scholar
• Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009;49(5):1571–1582. doi:10.1002/hep.22806
   PubMed Web of Science ®Google Scholar
• Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006;99(3):671–678. doi:10.1002/(ISSN)1097-4644
   PubMed Web of Science ®Google Scholar
• Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008;48(6):1810–1820. doi:10.1002/hep.22569
   PubMed Web of Science ®Google Scholar
• Latorre J, Moreno-Navarrete JM, Mercader JM, et al. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. Int J Obes (Lond). 2017;41(4):620–630. doi:10.1038/ijo.2017.21
   PubMed Web of Science ®Google Scholar
• Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122(8):2871–2883. doi:10.1172/JCI63539
   PubMed Web of Science ®Google Scholar
• Tsai WC, Hsu SD, Hsu CS, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122(8):2884–2897. doi:10.1172/JCI63455
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–3536. doi:10.1038/onc.2009.211
   PubMed Web of Science ®Google Scholar
• Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology. 2013;144(5):888–902. doi:10.1053/j.gastro.2013.02.032
   PubMedGoogle Scholar
• Akiyama TE, Ward JM, Gonzalez FJ. Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1alpha (HNF1alpha). Alterations in fatty acid homeostasis in HNF1alpha-deficient mice. J Biol Chem. 2000;275(35):27117–27122. doi:10.1074/jbc.M004388200
   PubMedGoogle Scholar
• Rebouissou S, Imbeaud S, Balabaud C, et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem. 2007;282(19):14437–14446. doi:10.1074/jbc.M610725200
   PubMedGoogle Scholar
• Lee YH, Magnuson MA, Muppala V, Chen SS. Liver-specific reactivation of the inactivated Hnf-1alpha gene: elimination of liver dysfunction to establish a mouse MODY3 model. Mol Cell Biol. 2003;23(3):923–932. doi:10.1128/MCB.23.3.923-932.2003
   PubMedGoogle Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–1131. doi:10.1172/JCI0215593
   PubMed Web of Science ®Google Scholar
• Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279(47):48865–48875. doi:10.1074/jbc.M409699200
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101(18):7100–7105. doi:10.1073/pnas.0402133101
   PubMed Web of Science ®Google Scholar
• Ai D, Chen C, Han S, et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest. 2012;122(4):1262–1270. doi:10.1172/JCI61919
   PubMed Web of Science ®Google Scholar
• Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49(2):399–409. doi:10.1194/jlr.M700443-JLR200
   PubMed Web of Science ®Google Scholar
• Li Z, Liu Q. Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity. Biochem Biophys Res Commun. 2018;496(4):1229–1235. doi:10.1016/j.bbrc.2018.01.176
   PubMed Web of Science ®Google Scholar
• Tao R, Xiong X, DePinho RA, Deng CX, Dong XC. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem. 2013;288(41):29252–29259. doi:10.1074/jbc.M113.481473
   PubMed Web of Science ®Google Scholar
• Song G, Zhu L, Ruan Z, Wang R, Shen Y. MicroRNA-122 promotes cardiomyocyte hypertrophy via targeting FoxO3. Biochem Biophys Res Commun. 2019;519(4):682–688. doi:10.1016/j.bbrc.2019.09.035
   PubMedGoogle Scholar
• Su L, Zhou L, Chen FJ, et al. Cideb controls sterol-regulated ER export of SREBP/SCAP by promoting cargo loading at ER exit sites. EMBO J. 2019;38(8). doi:10.15252/embj.2018100156.
   Google Scholar
• Li JZ, Lei Y, Wang Y, et al. Control of cholesterol biosynthesis, uptake and storage in hepatocytes by Cideb. Biochim Biophys Acta. 2010;1801(5):577–586. doi:10.1016/j.bbalip.2010.01.012
   PubMedGoogle Scholar
• Laudadio I, Manfroid I, Achouri Y, et al. A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation. Gastroenterology. 2012;142(1):119–129. doi:10.1053/j.gastro.2011.09.001
   PubMed Web of Science ®Google Scholar
• Wei S, Zhang M, Yu Y, et al. HNF-4alpha regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-treated HepG2 cells. Eur J Pharmacol. 2016;791:254–263. doi:10.1016/j.ejphar.2016.08.038
   PubMed Web of Science ®Google Scholar
• Cho SJ, Ferrell LD, Gill RM. Expression of liver fatty acid binding protein in hepatocellular carcinoma. Hum Pathol. 2016;50:135–139. doi:10.1016/j.humpath.2015.12.002
   PubMedGoogle Scholar
• Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43(3):515–524. doi:10.1002/(ISSN)1527-3350
   PubMed Web of Science ®Google Scholar
• Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet. 2002;32(2):312–315. doi:10.1038/ng1001
   PubMedGoogle Scholar
• Haddouche A, Bellanne-Chantelot C, Rod A, et al. Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): clinical, radiological and pathological characteristics in a French series. J Diabetes. 2019.
   PubMedGoogle Scholar
• Nakamura A, Ishidu K, Tajima T. Early onset of liver steatosis in a Japanese girl with maturity-onset diabetes of the young type 3 (MODY3). J Clin Res Pediatr Endocrinol. 2012;4(2):104–106. doi:10.4274/Jcrpe
   PubMedGoogle Scholar
• Shih DQ, Bussen M, Sehayek E, et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet. 2001;27(4):375–382. doi:10.1038/86871
   PubMed Web of Science ®Google Scholar
• Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98. doi:10.1016/j.cmet.2006.01.005
   PubMed Web of Science ®Google Scholar
• Pelletier L, Rebouissou S, Paris A, et al. Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology. 2010;51(2):557–566. doi:10.1002/hep.23362
   PubMedGoogle Scholar
• Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124(1):35–46. doi:10.1016/j.cell.2005.12.022
   PubMed Web of Science ®Google Scholar
• Chen J, Cooper AD, Levy-Wilson B. Hepatocyte nuclear factor 1 binds to and transactivates the human but not the rat CYP7A1 promoter. Biochem Biophys Res Commun. 1999;260(3):829–834. doi:10.1006/bbrc.1999.0980
   PubMedGoogle Scholar
• Chiang JY, Kimmel R, Stroup D. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene. 2001;262(1–2):257–265. doi:10.1016/S0378-1119(00)00518-7
   PubMed Web of Science ®Google Scholar
• Moore KJ, Rayner KJ, Suarez Y, Fernandez-Hernando C. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr. 2011;31:49–63. doi:10.1146/annurev-nutr-081810-160756
   PubMed Web of Science ®Google Scholar
• Wen J, Friedman JR. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest. 2012;122(8):2773–2776. doi:10.1172/JCI63966
   PubMedGoogle Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297. doi:10.1001/jama.2016.13985
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Bellanne-Chantelot C, Carette C, Riveline JP, et al. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes. 2008;57(2):503–508. doi:10.2337/db07-0859
   PubMed Web of Science ®Google Scholar